Loading Results
We have updated our Online Services Terms of Use and Privacy Policy. See our Cookies Notice for information concerning our use of cookies and similar technologies. By using this website or clicking “I ACCEPT”, you consent to our Online Services Terms of Use.

Metastatic Osteosarcoma Study

Study of Natalizumab as a Single Agent in Children, Adolescents and Young Adults with Recurrent, Refractory or Progressive Pulmonary Metastatic Osteosarcoma

cancer patient talking to physician
AGE: 5-30 years old
SEX AT BIRTH: All
HEALTHY PARTICIPANTS: No
TYPE: Interventional Study
CONDITION: Osteosarcoma
LOCATION: University Hospitals Rainbow Babies & Children’s

Learn More About This Research Study

For more information, please contact study coordinator, Kristin Leuchtag at 216-844-3332 or complete the form below.

Study Purpose

The purpose of this study is to evaluate if Natalizumab can be used safely and effectively as immunotherapy in children, adolescent and young adult patients with pOS. Natalizumab is currently Food and Drug Administration (FDA) approved for the treatment of T-cell mediated autoimmune disorders. The study team will evaluate the safety and tolerability of Natalizumab as well as the clinical response associated with Natalizumab treatment and evaluate overall survival.

Who Can Participate

Participants between 5 and 30 years of age diagnosed with Pulmonary Metastatic Osteosarcoma (pOS) may be eligible for this study.

I'm not a robot